Amicus Therapeutics Inc.

TheStreet's weekly guide to upgrades, downgrades and price-target changes includes Estee Lauder, Twitter and Uber.

Amicus tanks as analysts downgrade it after the company reported disappointing test results for its Pompe disease drug.

Jim Cramer says investors need to consider the bear the motivation, and they need to consider the big sellers they'll have to outrun.

Jim Cramer takes a look at FedEx, Funko, Amicus Therapeutics, Turning Point Brands, Sirius XM Radio, and more.

Jim Cramer looks ahead to the fourth quarter and has your game plan for next week.

Jim Cramer takes a look at Groupon, Wix.com, Las Vegas Sands, Paycom Software, Bojangles, FedEx, Amicus Therapeutics, Discovery Communications.

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

The South San Francisco, Calif.-based firm said Sept. 12 it had priced its underwritten public offering of 6.35 million shares at $55 apiece.

Teligent, FibroGen and Amicus Therapeutics were among the biotech stock movers in premarket trading on July 21.

In focus.

Big gains could be ahead for investors willing to stick with the stock, according to one firm.

Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.

Ionis Pharmaceuticals, Alnylam Pharmaceuticals, Amicus Therapeutics and Minerva Neurosciences were among the biotech movers in premarket trading on Monday.

Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.

Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Insiders at these companies -- including Occidental Petroleum and Six Flags Entertainment -- have been scooping up shares of their own stock lately.

Futures remain soft, but analysts believe rally still has steam.

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

Here's the 'rinse, wash and repeat' trade strategy that continues to be profitable for me.

Here are some cheap names I'm playing via covered-call orders.

Healthcare offers some rare bargains in the current market.

I'm eyeing these small cap names for 2024; and here's why I'm still skeptical on a soft landing.

Here's how to form an options play on Amicus Therapeutics.

Not all the news from the small biotech space is bad. One company in particular already has been gaining the attention of investors.

This midcap biotech name sets up well for a covered call strategy.

Amicus Therapeutics and Eiger BioPharmaceuticals set up well for using my covered call strategy.

I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.

Both these names reported third-quarter results last week.

These small biotech concerns are undervalued.

The two are homebuilding and biotech, and there are stocks within those sectors where I've parked my money.

Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.

The names include a veterinary drug concern plus companies with successful drugs on the market.

The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.

The combination of three charts gives me a bullish view on FOLD.

Despite the January rally, this biotech name and building materials firm still have further to rise.

I think M&A activity will pick up markedly going forward across the industry.

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Toyota's 'squeaky clean' image as the Prius brand is a bit foggy.

The veteran analyst explains what could happen to markets in 2025.

Here’s what retired Americans can expect for the year ahead.